|
|
Post by sportsrancho on Jan 18, 2017 15:28:06 GMT -5
I just DM him.
Then I saw this new tweet:
|
|
|
|
Post by alethea on Jan 18, 2017 15:51:37 GMT -5
I just DM him. Then I saw this new tweet: I tried unsuccessfully to send him a Direct Message on Twitter. It would not allow me - he doesn't follow me or somesuch. Thus ends my career as an author on Twitter. I read Nate, Mike, Afrezzauser and others on Twitter - never sent a DM. Good Lord, not that long ago I began to get comfortable with email. I can't keep up with the ever changing tech developments. I still prefer a landline. Hope he gets mine on ProBoards. |
|
|
|
Post by sportsrancho on Jan 18, 2017 16:07:29 GMT -5
DM me on Twitter. What's your handle? Do I follow you? I'll copy it and DM it to Sam. Or follow me and then I will DM you:-)
|
|
|
|
Post by sportsrancho on Jan 18, 2017 16:09:23 GMT -5
I DM Mike privately too.
|
|
|
|
Post by promann on Jan 18, 2017 16:48:06 GMT -5
Hey sports what's the deal? Is he looking for people to do a Comercial? Why does he want to talk to typ 2 users? If you don't know please speculate..
Thanks
|
|
|
|
Post by harryx1 on Jan 18, 2017 16:56:25 GMT -5
|
|
|
|
Post by sportsrancho on Jan 18, 2017 17:02:03 GMT -5
Hey sports what's the deal? Is he looking for people to do a Comercial? Why does he want to talk to typ 2 users? If you don't know please speculate.. Thanks I don't have a clue. He maybe wants to share their experience somehow? Look what WildPig just said to me... Jan. 18 at 1:44 PM wildpig $MNKD try very very hard to remember this is a financial board, not a medical board not a rescue misson, not a feel good thread ok? rooksleanne 1 Share $MNKD If you are a T2 and are on Afrezza you can also DM Sam. Or DM me and I will send to Mike. twitter.com/afrezzauser/sta... |
|
|
|
Post by promann on Jan 18, 2017 17:20:33 GMT -5
Hey sports what's the deal? Is he looking for people to do a Comercial? Why does he want to talk to typ 2 users? If you don't know please speculate.. Thanks I don't have a clue. He maybe wants to share their experience somehow? Look what WildPig just said to me... Jan. 18 at 1:44 PM wildpig $MNKD try very very hard to remember this is a financial board, not a medical board not a rescue misson, not a feel good thread ok? rooksleanne 1 Share $MNKD If you are a T2 and are on Afrezza you can also DM Sam. Or DM me and I will send to Mike. twitter.com/afrezzauser/sta... Lol. Really nice! I figured I would ask what everyone else was wondering. Sorry to put you on the spot.. Thanks. For everything |
|
|
|
Post by sportsrancho on Jan 18, 2017 18:32:30 GMT -5
What's weird is he said that to me privately on ST. ( So no one could see) But it wasn't a DM because I don't follow him. Not sure how that works on ST? But I found it a little strange. Kinda like..shut the hell up! Wow, it takes all kinds, stay strong. Anything to help get the word out, you would think people would be thanking you. Nope, very sad. sayhey they say he is frag on YMB. I don't know... but after he said it I posted this:-)) |
|
|
|
Post by harryx1 on Jan 19, 2017 9:54:57 GMT -5
|
|
|
|
Post by Cowgirl on Jan 21, 2017 20:37:48 GMT -5
Should we be concerned, when after a few years of Afrezza being sold by Sanofi and Mannkind, the Chief Commercial Officer, is trying to find a T2 user of Afrezza via twitter?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 21, 2017 21:12:25 GMT -5
Should we be concerned, when after a few years of Afrezza being sold by Sanofi and Mannkind, the Chief Commercial Officer, is trying to find a T2 user of Afrezza via twitter? you forgot to add, numerous advocates - I think , most of the Afrezza users are the pull from advocate channels, and very limited # from push channel |
|
|
|
Post by mbseeking on Jan 21, 2017 21:49:01 GMT -5
Should we be concerned, when after a few years of Afrezza being sold by Sanofi and Mannkind, the Chief Commercial Officer, is trying to find a T2 user of Afrezza via twitter? you forgot to add, numerous advocates - I think , most of the Afrezza users are the pull from advocate channels, and very limited # from push channel Yeah I thought that too. T2 was always the biggest opp for this but most of the social media noise is T1. After this thought I went back to the JP Morgan meeting . Seems that the new titration packs are about addressing T2 better. Late, but better than never. |
|
|
|
Post by sayhey24 on Jan 22, 2017 9:35:58 GMT -5
you forgot to add, numerous advocates - I think , most of the Afrezza users are the pull from advocate channels, and very limited # from push channel Yeah I thought that too. T2 was always the biggest opp for this but most of the social media noise is T1. After this thought I went back to the JP Morgan meeting . Seems that the new titration packs are about addressing T2 better. Late, but better than never. The Sanofi target market was T2s which are no longer getting control on the pills. The problem is two fold; the doctors; and the T2s. The doctors have to understand what afrezza is and is not when compared to other RAAs and basals. They have to see the value in providing near-natural pancreatic function for meals. The patients should test prior to a meal but must test about 1 hour later and re-dose to mimic for phase 2 insulin release as afrezza will only provide phase 1 release. Pretty simple in the general case. Here is the problem, thats lots of test strips and money and some of this target market is selling Medicaid funded strips for cash. Bottom line is few of these T2s is going out to buy a CGM. Second, multiple test and dosing is not in the dosing instructions and sure is not how the 175 study was done. Good news, Dexcom just got Medicare B "partial" cost coverage. Better yet the Abbott Libre is starting to make an impact with some doctors and getting the reader is about $100 which saves on the test strip costs and the finger pokes and eliminates the black market and results can be sent to the doctor. Packaging is a whole other issue; the 4s, 8s, and 12s all need to be packaged separate. There should be a 2 unit for post meal and for snack adjustments and they will need it for the kids. To mimic phase 1 and phase 2 minimally you are looking at 180 cartridges a month but really more. The last I saw from Mike C. was that afrezza pricing is just fine the way it is. If a box of 90 is priced at $300 then afrezza is about 2x the rest of the market. Houston, we have a problem. The good news is we got Apollo 13 home safe and with CGM technology and proper marketing and money Mannkind can make afrezza huge. |
|
|
|
Post by agedhippie on Jan 22, 2017 10:52:34 GMT -5
Yeah I thought that too. T2 was always the biggest opp for this but most of the social media noise is T1. After this thought I went back to the JP Morgan meeting . Seems that the new titration packs are about addressing T2 better. Late, but better than never. The Sanofi target market was T2s which are no longer getting control on the pills. The problem is two fold; the doctors; and the T2s. The doctors have to understand what afrezza is and is not when compared to other RAAs and basals. They have to see the value in providing near-natural pancreatic function for meals. The patients should test prior to a meal but must test about 1 hour later and re-dose to mimic for phase 2 insulin release as afrezza will only provide phase 1 release. Pretty simple in the general case. Here is the problem, thats lots of test strips and money and some of this target market is selling Medicaid funded strips for cash. Bottom line is few of these T2s is going out to buy a CGM. Second, multiple test and dosing is not in the dosing instructions and sure is not how the 175 study was done. Good news, Dexcom just got Medicare B "partial" cost coverage. Better yet the Abbott Libre is starting to make an impact with some doctors and getting the reader is about $100 which saves on the test strip costs and the finger pokes and eliminates the black market and results can be sent to the doctor. Packaging is a whole other issue; the 4s, 8s, and 12s all need to be packaged separate. There should be a 2 unit for post meal and for snack adjustments and they will need it for the kids. To mimic phase 1 and phase 2 minimally you are looking at 180 cartridges a month but really more. The last I saw from Mike C. was that afrezza pricing is just fine the way it is. If a box of 90 is priced at $300 then afrezza is about 2x the rest of the market. Houston, we have a problem. The good news is we got Apollo 13 home safe and with CGM technology and proper marketing and money Mannkind can make afrezza huge. Early uptake of Afrezza in the T2 lifecycle is going to be a compliance nightmare. You are asking people to carry around the inhaler and use it at every meal and then check and possibly reuse after an hour or so. That is far more effort than most people will want to expend and the doctors know it. The easier route is to stick with the standard of care have them on oral meds once a day until that fails and then have them take a single daily basal insulin shot. Less to do = better compliance. The benefit of targeting the T1 market is that compliance is not optional. Don't take your insulin and it all gets very nasty very fast. There is probably a market in the final stages of T2 where people are on both basal and RAA insulin. The catch is that by then they tend to be very insulin resistant so they need a lot of insulin - there may be a need for much higher unit cartridges. The problem you run into with the Libre is that you do not have access to the data until you next see the doctor. This means you are still going to be pricking your finger and using strips to find out where you are anyway. You cannot get rid of the mixed boxes though. As an example I guess I would use mostly 8u doses so I get one (maybe two) box of 8u, one box of 4u+8u, and one box of 8u+12u. If it's packaged purely by unit size I am going to end up throwing away 4u and 12u cartridges which is going to push up costs. |
|
